Ron Price Net Worth

The estimated Net Worth of Ron Price is at least $682 Thousand dollars as of 21 April 2022. Mr. Price owns over 40,755 units of Accelerate Diagnostics Inc stock worth over $89,648 and over the last 7 years he sold AXDX stock worth over $0. In addition, he makes $592,255 as Senior Vice President, Head of Commercial Operations, and Americas at Accelerate Diagnostics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Price AXDX stock SEC Form 4 insiders trading

Ron has made over 3 trades of the Accelerate Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 40,755 units of AXDX stock worth $65,616 on 21 April 2022.

The largest trade he's ever made was exercising 40,755 units of Accelerate Diagnostics Inc stock on 21 April 2022 worth over $65,616. On average, Ron trades about 6,966 units every 55 days since 2018. As of 21 April 2022 he still owns at least 55,682 units of Accelerate Diagnostics Inc stock.

You can see the complete history of Mr. Price stock trades at the bottom of the page.

Ron Price biography

Ron Price serves as Senior Vice President, Head of Commercial Operations, Americas of the Company. Mr. Price has over 20 years of commercial operations experience and a proven track record of leading sales and marketing teams to achieve double-digit revenue growth and strong bottom-line performance. Prior to joining the Company, Mr. Price served as Vice President, Commercial Operations for Roche Point of Care managing all commercial responsibilities across three separate product lifecycles. In addition, Mr. Price held a number of sales, marketing, and leadership roles with Ventana Medical Systems from 2001 to 2012 following 5 years at Bayer Healthcare Diagnostics. Mr. Price holds a B.S. in Clinical Laboratory Sciences, Cytology from the University of Oklahoma.

What is the salary of Ron Price?

As the Senior Vice President, Head of Commercial Operations, and Americas of Accelerate Diagnostics Inc, the total compensation of Ron Price at Accelerate Diagnostics Inc is $592,255. There are 3 executives at Accelerate Diagnostics Inc getting paid more, with John Phillips having the highest compensation of $12,300,900.

How old is Ron Price?

Ron Price is 56, he's been the Senior Vice President, Head of Commercial Operations, and Americas of Accelerate Diagnostics Inc since 2017. There are 8 older and 6 younger executives at Accelerate Diagnostics Inc. The oldest executive at Accelerate Diagnostics Inc is Jack Schuler, 79, who is the Independent Director.

What's Ron Price's mailing address?

Ron's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.

Insiders trading at Accelerate Diagnostics Inc

Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg, and Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.

What does Accelerate Diagnostics Inc do?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Complete history of Mr. Price stock trades at Accelerate Diagnostics Inc

Accelerate Diagnostics Inc executives and stock owners

Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Phillips,
  Chief Executive Officer, Chief Operating Officer, Director
• Steve Reichling,
  Chief Financial Officer
• Jack Phillips,
  CEO, Pres & Director
• Ron Price,
  Senior Vice President, Head of Commercial Operations, Americas
• Roland Diggelmann,
  Independent Director
• Louise Francesconi,
  Independent Director
• Steve Reichling,
  CFO & Chief Accounting Officer
• Ron Price,
  Chief Commercial Officer of Americas
• Charles Watts,
  Independent Director
• Frank ten Brink,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Jack Schuler,
  Independent Director
• Mark Miller,
  Independent Director
• Thomas Brown,
  Independent Director
• John Patience,
  Independent Chairman of the Board
• Nedal Safwat,
  Chief Strategy Officer
• Dr. Lawrence Mertz,
  Sr. VP and Head of R&D
• John Meduri,
  Chief Strategy Officer
• Laura Costa,
  Sr. VP & Head of Global Customer Support
• Cherif Bousselham,
  Sr. VP & Head of Sales - EMEA
• Gretchen Strohminger,
  Sr. VP and Head of HR & Culture
• Michael Bridge,
  Sr. VP, Gen. Counsel & Sec.
• Laura Pierson,
  Investor Relations Officer
• Larry N Feinberg,
  10% owner
• Pete Bantock,
  CHIEF COMMERCIAL OFFICER
• Lawrence Mehren,
  PRESIDENT AND CEO
• Marran H. Ogilvie,
  Director
• Jennifer Regan,
  Director
• Mark S. Black,
  Director
• Ventures, Llc Abeja,
  10% owner
• Romney Humphries,
  Chief Scientific Officer
• Larry Michael Mertz,
  Chief Technology Officer
• Hany Massarany,
  Director
• Jack Phillips,
  Chief Executive Officer
• Wayne Burris,
  Director
• David Patience,
  Chief Financial Officer